Johnson & Johnson announced the cessation of late-stage trials for a depression drug over insufficient effectiveness in treating major depressive disorder. Meanwhile, the U.S. Centers for Disease Control and Prevention plans a study on autism and vaccines, despite existing research denying such links.
About the Author
